News

Keyword Search

Year

Apr 07, 2021

CTI BioPharma to Present at the 20th Annual Needham Virtual Healthcare Conference on Wednesday, Apr. 14

SEATTLE , April 7, 2021 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ: CTIC) today announced that management will provide a corporate overview at the 20th Annual Needham Virtual Healthcare Conference at 3:00 p.m. EST . The conference will be held in a virtual meeting format.

Apr 02, 2021

CTI BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SEATTLE , April 2, 2021 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ: CTIC) today announced that the Compensation Committee of its Board of Directors granted equity awards to three new employees as equity inducement awards outside of the Company's Amended and Restated 2017 Equity Incentive Plan

Mar 31, 2021

CTI BioPharma Corp. Announces Pricing of its Public Offering of Common Stock and Preferred Stock

SEATTLE , March 31, 2021 /PRNewswire/ -- CTI BioPharma Corp. (Nasdaq: CTIC) ("CTI"), a biopharmaceutical company focused on the acquisition, development and commercialization of novel targeted therapies covering a spectrum of blood-related cancers, today announced the pricing of its previously

Mar 31, 2021

CTI BioPharma Corp. Announces Proposed Public Offering of Common Stock and Preferred Stock

Mar 31, 2021

CTI BioPharma Announces Completion of Rolling Submission of New Drug Application (NDA) for Pacritinib in Myelofibrosis Patients with Severe Thrombocytopenia

- Commercial Preparations Underway to Support Potential Approval and Launch of Pacritinib in the United States in 2021 - SEATTLE , March 31, 2021 /PRNewswire/ -- CTI BioPharma Corp. (Nasdaq: CTIC) today announced that it has completed a rolling New Drug Application ("NDA") submission to the U.S.

Mar 22, 2021

Phase 1 Trial Demonstrates Encouraging Clinical Benefit and Promising Safety Profile of Pacritinib for the Prevention of Graft-Versus-Host Disease Published in Clinical Cancer Research

- Investigator-sponsored Phase 1 Trial of Acute GVHD Prophylaxis Following Allogeneic Hematopoietic Cell Transplantation Shows Encouraging Clinical Benefit and Promising Safety Profile when Combining Pacritinib 100 mg BID with Standard Immunosuppressive Therapy - - Phase 2 Investigator-sponsored

Mar 17, 2021

CTI BioPharma Reports Fourth Quarter and Full Year 2020 Financial Results

- Completion of Rolling NDA Submission for Pacritinib for the Treatment of Myelofibrosis Patients with Severe Thrombocytopenia Expected this Month - - Commercialization Activities on Track to Support a Potential Approval and Launch of Pacritinib in the United States in 2021 - - Management to Host

Mar 12, 2021

CTI BioPharma to Report Fourth Quarter and Full Year 2020 Financial Results on March 17, 2021

SEATTLE , March 12, 2021 /PRNewswire/ -- CTI BioPharma Corp. ( CTI BioPharma ) (NASDAQ: CTIC) today announced that management plans to report its fourth quarter and full year 2020 financial results on Wednesday, March 17, 2021 , after the close of the U.S. financial markets.

Mar 08, 2021

CTI BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SEATTLE , March 8, 2021 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ: CTIC) today announced that the Compensation Committee of its Board of Directors granted equity awards to two new employees with a grant date of March 8, 2021 , as equity inducement awards outside of the Company's Amended and

Feb 25, 2021

CTI BioPharma to Present at the Cowen 41st Annual Health Care Conference on Thursday, Mar. 4

SEATTLE , Feb. 25, 2021 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ: CTIC) today announced that management will provide a corporate overview at the Cowen 41st Annual Health Care Conference at 12:10 p.m. EST . The conference will be held in a virtual meeting format.

Pagination

Current page 1
Page 2
Next page
Last page

Investors

News

News

–

–

–

–